The company presented data from two studies, one evaluating the differentiated MoA of eblasakimab vs dupilumab in skin punch biopsies of AD patients along with the role of eblasakimab in COPD using ex vivo models of human lungs evaluating the airway hyperresponsiveness (AHR) in the lung tissue using IL-4 & IL-13
The results from the study depicted that eblasakimab significantly reduced Th2 cytokines IL-13, IL-4, sCD40L, IL-17F, CCL3 & CCL4 expressions vs dupilumab whereas in COPD models, eblasakimab reduced airway constrictions & enhanced dilation
Results from both studies were presented at the DDDS 2023 & further data from both ongoing studies are expected to be presented at forthcoming scientific meetings
Ref: ASLAN | Image: ASLAN
Related News:- ASLAN Pharmaceuticals Entered into a License Agreement with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
